Strategic partnerships Haystack MRD is a Quest Diagnostics portfolio with a track record of research collaborations with institutions like Rutgers Cancer Institute, TriSalus Life Sciences, Lisata Therapeutics, and participation in multiple oncology conferences. This presents opportunities to expand co-development, joint studies, and contract-based MRD testing for oncology trials and cancer care programs.

Clinical adoption potential With a two-decade clinical development legacy and a tumor-informed ultra-sensitive ctDNA MRD test, target mid- to late-stage cancer centers and specialty clinics focusing on post-treatment surveillance and precision oncology to drive adoption of Haystack MRD as a standard MRD assessment tool.

Expansion through events Active presence at key conferences (ASCO GI, SGO, SSO, Community Oncology Conference) signals readiness to engage payer discussions, share outcomes, and generate lead opportunities with oncology professionals seeking MRD-guided treatment decisions.

Financial viability Current revenue range suggests a growing, mid-sized biotech services business with potential for scale through strategic collaborations, licensing, or expanded payer-reimbursed MRD testing across broader cancer types and longitudinal monitoring.

Technology & data edge Leveraging precision genomics, ctDNA analytics, and a robust tech stack positions Haystack MRD to offer integrated data services, multi-center study support, and potential customization for pharmaceutical sponsors conducting MRD-driven trials.